AI assistant
AMGEN INC — Director's Dealing 2025
Feb 11, 2025
29819_dirs_2025-02-10_b9d1102c-c49e-4679-9743-5f232d5db07c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-02-07
Reporting Person: Graham Jonathan P (EVP & Gen. Counsel & Secy.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-07 | Common Stock | M | 25045 | $156.35 | Acquired | 54032 | Direct |
| 2025-02-07 | Common Stock | S | 25045 | $293.1173 | Disposed | 28987 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-07 | Nqso (Right to Buy) | $156.35 | M | 25045 | Disposed | 2026-05-03 | Common Stock (25045) | Direct |
Footnotes
F1: These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
F2: The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F3: These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.